Polynucleotide for nosocomial staphylococcus infection treatments

Multiple-resistant (methicillin-resistant) Staphylococcus aureus (MRSA) is now an endemic hospital-acquired pathogen in many hospitals around the world. This infection is even more alarming in the 21st century as antibiotic resistance developed. So far, long-lasting solutions have not been established.

This innovation enables the development of a new approach for anti-biotherapy against staphylococcal infection. Indeed, a regulatory polynucleotide inhibits the expression of the sbi gene involved in a bacteria key process to evade the host immune system. Sbi protein recruits IgG immunoglobulins and complement factor C3 involved in all 3 activation pathways of the complement resulting in the trapping of IgG and C3 proteins and blocking their role as immune system activators. Increasing this polynucleotide in bacteria decreases sbi expression enabling the host immune system to play is role again.

In vivo studies on mouse model running.